The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. European Commission approves Evrysdi for the treatment of 5qSMA

    Following our request for regular updates, Roche is delighted to inform us that today the European Commission (EC) approved Evrysdi™ (risdiplam), the first and only at home treatment for SMA, with proven efficacy in adults, children and babies two months and older. Risdiplam was reviewed under the European Medicine Agency’s (EMA) accelerated assessment programme, intended […]


  2. Community update on access to Spinraza in Europe

    In response to our request, Biogen has provided us with an update on access to SPINRAZA™ (nusinersen). There are now 29 European countries that have access to nusinersen via regular reimbursement. Since the last report, an updated situation can be found for Switzerland. As you can see from the table, there is a range of […]